Overview

• US healthcare distributor's fiscal Q4 revenue rose 6% yr/yr but missed analyst expectations

• Adjusted EPS for fiscal Q4 rose 16% and beat analyst expectations

• Company expanded share repurchase program, entering $2.25 bln accelerated buyback

Outlook

• McKesson sees fiscal 2027 adjusted EPS between $43.80 and $44.60

• Company reaffirms long-term adjusted EPS growth target of 13% to 16%

• McKesson targets long-term segment operating profit growth of 5%-8% for North American Pharmaceutical, 13%-16% for Oncology & Multispecialty, 10%-13% for Prescription Technology Solutions

Result Drivers

• ONCOLOGY & SPECIALTY GROWTH - Q4 revenue growth was driven by increased distribution of oncology and multispecialty products, including contributions from acquisitions

• HIGHER PRESCRIPTION VOLUMES - Growth in the North American Pharmaceutical segment was due to increased prescription transaction volumes, partially offset by lower contributions from branded pharmaceuticals

• ADJUSTED EPS DRIVERS - Adjusted EPS growth was driven by operational growth, acquisitions in Oncology & Multispecialty, a lower share count, and a lower tax rate

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.